These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34605124)

  • 1. Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Borodavkin P; Sheridan W; Coelho C; Oštarijaš E; Zaïr ZM; Miras AD; McGowan B; le Roux CW; Vincent RP; Dimitriadis GK
    Diabetes Obes Metab; 2022 Feb; 24(2):337-342. PubMed ID: 34605124
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
    Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
    Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
    Polyzos SA; Goulas A; Papaioannidou P
    Curr Med Chem; 2023; 30(22):2476-2479. PubMed ID: 36617715
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).
    Ghosal S; Datta D; Sinha B
    Sci Rep; 2021 Nov; 11(1):22063. PubMed ID: 34764398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
    Polyzos SA; Frühbeck G; Kiortsis DN
    Curr Pharm Des; 2023; 29(41):3263-3265. PubMed ID: 38111116
    [No Abstract]   [Full Text] [Related]  

  • 11. Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
    Nakouti T; Karagiannis AK; Tziomalos K; Cholongitas E
    Curr Vasc Pharmacol; 2015; 13(5):649-57. PubMed ID: 25412688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
    Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Carbone LJ; Angus PW; Yeomans ND
    J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?
    Mantovani A
    Dig Liver Dis; 2021 Dec; 53(12):1673-1674. PubMed ID: 34366254
    [No Abstract]   [Full Text] [Related]  

  • 17. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
    Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
    Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
    Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
    Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.